Pediatric Self-Assessment Program (PEDSAP) 2025 (L259156)
ACPE Numbers: Various – see listing below Release Date: July 15, 2025 Expiration Dates: July 15, 2026 Activity Type: Application-based CE Credits: 20.5 contact hours (BPS and ACPE) Activity Fee: $88 (ASHP member); $132 (non-member)
Activity Overview
This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 9 learning modules (see table below) and provides up to 20.5 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCPPS recertification approved by the BPS.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.
Board certified pharmacists are eligible to receive up to 20.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCPPS.
Learning Activity
Passing Score
Credit Information
Chapter: Analgesia and Sedation
73%
2.5 Contact Hours
BPS: BCPPS ACPE: 0217-9999-25-158-H01-P
Chapter: Sepsis
66%
2.0 Contact Hours
BPS: BCPPS ACPE: 0217-9999-25-165-H01-P
Chapter: Pulmonary Hypertension
73%
3.0 Contact Hours
BPS: BCPPS ACPE: 0217-9999-25-164-H01-P
Chapter: Hyponatremia
60%
3.0 Contact Hours
BPS: BCPPS ACPE: 0217-9999-25-161-H01-P
Chapter: Total Parenteral Nutrition
73%
2.5 Contact Hours
BPS: BCPPS ACPE: 0217-9999-25-166-H01-P
Chapter: Direct Oral Anticoagulant Use
66%
2.0 Contact Hours
BPS: BCPPS ACPE: 0217-9999-25-159-H01-P
Case Series: Enteral Tube Medication Administration
Chapter: Analgesia and Sedation ACPE #: 0217-9999-25-158-H01-P
Distinguish between the different types of analgesia and sedation in a pediatric patient.
Apply the appropriate analgesia and sedation scale based on patient characteristics.
Evaluate the latest analgesia and sedation guidelines and their applicability to the pediatric patient population.
Demonstrate understanding of medications used for analgesia and sedation and their effects on neurodevelopment.
Assess the challenges associated with managing analgesia and sedation in the pediatric patient.
Chapter: Sepsis ACPE #: 0217-9999-25-158-H01-P
Assess current consensus criteria for identifying pediatric sepsis and septic shock.
Evaluate available screening tools used to promote early recognition of pediatric sepsis.
Analyze the role of balanced crystalloid fluids in pediatric patients with septic shock or sepsis-associated organ dysfunction.
Devise empiric antimicrobial therapy regimens for pediatric patients with suspected sepsis and septic shock.
Evaluate vasoactive and inotrope medications, as well as adjunct and advanced therapies for managing fluid-refractory and catecholamine-resistant shock in pediatric patients.
Justify the implementation of sepsis bundles at the institutional and caregiver level to improve patient outcomes.
Distinguish between the causes of and the differential diagnoses of hyponatremia in pediatric patients.
Devise a plan for sodium replacement therapy in pediatric patients with syndrome of inappropriate antidiuretic hormone secretion.
Evaluate the role and place in therapy of conivaptan and tolvaptan in pediatric patients.
Design a plan for managing serum sodium correction with current therapies in pediatric patients.
Chapter: Total Parenteral Nutrition ACPE #: 0217-9999-25-166-H01-P
Apply an understanding of clinical guideline updates to the pediatric and neonatal populations.
Assess the differences between injectable lipid emulsion (ILE) products, and recommend appropriate interventions for the prevention or treatment of essential fatty acid deficiency (EFAD) and intestinal failure–associated liver disease (IFALD).
Demonstrate knowledge of hypertriglyceridemia management in parenteral nutrition (PN) and place in therapy for carnitine supplementation.
Distinguish which trace metal product is appropriate given specific patient parameters.
Apply knowledge of factors affecting the solubility of calcium and phosphorus in PN to prevent or reduce risk of precipitation.
Chapter: Direct Oral Anticoagulant Use ACPE #: 0217-9999-25-159-H01-P
Justify the role and place for standard of care anticoagulants and direct oral anticoagulants (DOACs).
Distinguish differences among DOACs that affect safety and efficacy.
Devise a management plan for anticoagulant therapy in pediatric patients around procedures and bleeding.
Detect circumstances in which DOAC use is not favorable in pediatric patients.
Case Series: Enteral Tube Medication Administration ACPE #: 0217-9999-25-160-H01-P
Assess a pediatric patient for appropriateness of an enteral feeding tube.
Classify the appropriateness of a medication for enteral tube administration based on the medication’s properties, the type of enteral tube, and the location of the feeding tube’s distal end.
Compose a plan for appropriate administration of medications through an enteral feeding tube, including dose preparation and flushing procedures.
Develop strategies to reduce the risk of clogging enteral tubes while administering medications.
Case Series: Illicit Drug Toxicology ACPE #: 0217-9999-25-162-H01-P
Evaluate the symptoms of cannabis exposure in a young child versus an adolescent.
Distinguish between cannabis toxicity and synthetic cannabinoid toxicity.
Assess the role of naloxone in the management of sedative toxicity.
Apply diagnostic criteria for serotonin toxicity to a patient case.
Devise an acute treatment plan for a pediatric patient presenting with 3,4-methylenedioxymethamphetamine toxicity.
Case Series: Kidney Replacement Therapies ACPE #: 0217-9999-25-163-H01-P
Distinguish the differences in indications among various forms of kidney replacement therapy (KRT) in pediatric patients.
Assess the effects of KRT on medication dosing in pediatric patients.
Estimate the level of residual kidney function in a pediatric patient receiving KRT.
Devise a medication dosing plan for a pediatric patient receiving KRT.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP require that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Consultancies: Kim W. Benner (Accord Biopharma); Rachel Meyers (CMP Pharma)
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
Complete the attestation statement
Review all content
Complete and pass the assessments
Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
